Seminars in Arthroplasty
Volume 21, Issue 2 , Pages 80-84 , June 2010

Deep Vein Thrombosis Propylaxis: Better Living Through Chemistry-Affirms

  • Bryant Ho, BA
    • ,
  • Michael H. Huo, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Michael H. Huo, MD, Department of Orthopedic Surgery, UT Southwestern Medical Center at Dallas, 1801 Inwood Road, Dallas, TX 75390

References 

  1. Hall M, Owings M. 2000 National Hospital discharge survey. Adv Data. 2002;329:1–18
  2. Hervey S, Purves H, Guller U, et al. Provider volume of total knee arthroplasties and patient outcomes in the HCUP-Nationwide inpatient sample. J Bone Joint Surg Am. 2003;85:1775–1783
  3. Pellegrini V. Warfarin prophylaxis for orthopaedic venous thromboembolic disease. Instr Course Lect. 2002;51:491–498
  4. Lieberman J, Geerts W. Prevention of venous thromboembolism after total hip and knee arthroplasty. J Bone Joint Surg Am. 1994;76:1239–1250
  5. Brendle T. Surgical Care Improvement Project and the perioperative nurse's roleo. AORN J. 2007;86:84–101
  6. Surgical care improvement project: Percent of surgery patients who received appropriate VTE prophylaxis within 24 hours prior to surgery to 24 hours after surgery. Centers for Medicare & Medicaid Services (CMS), The Joint Commission; 2008;
  7. Deep vein thrombosis/pulmonary embolism. Fed Regist [serial on the Internet]. 2008;73(161):48480–48482http://edocket.access.gpo.gov/2008/pdf/E8-17914.pdf
  8. Geerts W, Bergvist D, Pineo G, et al. American College of Chest Physicians Prevention of Venous Thromboembolism (American College of Chest Physicians evidence-based clinical practice guidelines (ed 8)). Chest. 2008;133(suppl 6):381S–453S
  9. American Academy of Orthopaedic Surgeons. Clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty (Adopted by the American Academy of Orthopaedic Surgeons Board of Directors). http://www.aaos.org/research/guidelines/PE_guideline.pdfAccessed September 14, 2009
  10. Bozic K, Vail T, Pekow P, et al: Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty (in press)
  11. Brown G. Venous thromboembolism prophylaxis after major orthopaedic surgery: A pooled analysis of randomized controlled trials. J Arthroplasty. 2009;24:77–83
  12. Enyart J, Jones R. Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. Ann Pharmacother. 2005;39:1002–1007
  13. Samama M, Cohen A, Darmon J, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients (Prophylaxis in Medical Patients with Enoxaparin Study Group). N Engl J Med. 1999;34:793–800
  14. Leizorovicz A, Cohen A, Turpie A, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–879
  15. Anderson F, Ayers D, Colwell C, et al. Bleeding concerns drive practices of orthopedic surgeons in prevention of venous thromboembolism in primary hip and knee arthroplasty. In: Presented at the International Society of Thrombosis and Hemostasis Meeting. Boston, MA. July 2009;
  16. Anderson F, Lieberman J, Pellegrini V, et al. Practices in prevention of venous thromboembolism in primary hip and knee arthroplasty vary with operative volume of surgeons: Findings from a survey of US orthopedic surgeons. In: Presented at the International Society of Thrombosis and Hemostasis Meeting. Boston, MA. July 2009;
  17. Eriksson B, Borris L, Friedman R, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765–2775
  18. Lassen M, Gallus A, Pineo G, et al. Randomized double-blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: The ADVANCE-1 trial. Blood. 2008;112:17–18
  19. Buller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis: The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6:1313–1318
  20. Eriksson B, Dahl O, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178–2185
  21. Caprini J, Hwang E, Hantel S, et al. The oral direct thrombin inhibitor dabigatran etexilate is effective and safe for the prevention of major venous thromboembolism following orthopaedic surgery. In: Presented at the 21st Congress of the International Society on Thrombosis and Hemostasis, Geneva. Switzerland. 2007;
  22. Lassen M, Davidson B, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis after knee replacement. J Thromb Haemost. 2007;5:2368–2375
  23. Eriksson B, Turpie A, Lassen M, et al. YM150, an oral direct factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery: A dose escalation study. Blood. 2005;106:530–531
  24. Agneli G, Haas S, Kruger K, et al. A phase II study of the safety and efficacy of a novel oral fXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR. Blood. 2005;106:85
  25. Eriksson B, Dahl O, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949–956
  26. Ginsberg J, Davidson B, Comp P, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1–9
  27. Streiff M, Haut E. The CMS ruling on venous thromboembolism after total knee or hip arthroplasty: Weighing the risks and benefits. JAMA. 2009;301:1063–1065
  28. Turpie A, Lassen M, Davidson B, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomized trial. The Lancet. 2009;9676:1673–1680

PII: S1045-4527(09)00097-2

doi: 10.1053/j.sart.2009.12.011

Seminars in Arthroplasty
Volume 21, Issue 2 , Pages 80-84 , June 2010

Article Tools